Blueprint Medicines is a biopharmaceutical company focused on developing therapies for genomically-defined diseases driven by abnormal kinase activation. The Company systematically and reproducibly identifies kinase drug targets that are drivers of genomically defined diseases and crafts kinase inhibitors to transform the lives of patients suffering from devastating diseases. The Company built a platform that integrates a novel target discovery engine and a proprietary compound library and has a pipeline of product candidates generated from this platform. One of the Company’s lead product candidates, Avapritinib, is in development for the treatment of systemic mastocytosis (SM) and a defined subset of patients with gastrointestinal stromal tumors (GIST). The Company’s other lead drug candidate, BLU-667, is in development for the treatment of RET mutant cancers. The Company anticipates filing an NDA in 1Q 2019 in NSCLC and in 1H 2020 in MTC based on the Phase II data. Blueprint is also developing BLU-554 for the treatment of a defined subset of patients with hepatocellular carcinoma (HCC) and BLU-782 for the treatment of fibrodysplasia ossificans progressive (FOP).